Inner-core lipopolysaccharide (LPS) from Neisseria meningitidis is under investigation as a vaccine for prevention of meningococcal disease caused by N. meningitidis serogroup B (NmB). We investigated the functional activity of murine monoclonal antibody (MAb) B5 that recognizes a highly conserved (galE) LPS epitope. Three patterns of MAb reactivity were observed in N. meningitidis by Western blot, depending on the relative prevalence of sialylated, nonsialylated, and/or truncated LPS glycoforms. Three representative N. meningitidis strains (8047, M986, and 2996) were investigated with MAb B5 in functional assays in vitro and in vivo. MAb B5 completely protected infant rats against bacteremia caused by 8047, partially protected against 2996, and had no protective activity against M986. Thus, an inner-core LPS epitope can be a target for protective immunity, but the affinity of MAb B5 may only be sufficient to mediate protection against NmB strains possessing at least some truncated glycoforms.
have been available for many years. These vaccines are effective in older children and adults but are poorly immunogenic in young children, the age group at greatest risk of developing meningococcal disease. This poor immunogenicity is attributed to a lack of T cell help and the host's immature immune system [1] . Group C meningococcal polysaccharide has been conjugated to carrier proteins (tetanus toxoid or CMR 197 ) [2] , and the resulting conjugate vaccines have been demonstrated to be safe and highly immunogenic in infants as young as 2 months [3] . These conjugate vaccines also have been shown to elicit long-lasting T cell-dependent immune responses characterized by immunological memory and high-avidity bactericidal anti-capsular polysaccharide antibodies [4, 5] . Group C strains are a common cause of meningococcal disease in North America and many European countries. In 1999, the first group C meningococcal conjugate vaccine was licensed and introduced in the United King-dom [3] , and this vaccine has been highly successful in eliminating most serogroup C disease [6] .
Currently, no meningococcal vaccines are available in Europe or North America for prevention of meningococcal disease caused by N. meningitidis group B (NmB) [2, 6] . The group B capsular polysaccharide is an autoantigen [7, 8] the use of which as the basis of a vaccine raises important safety issues [4, 9] . Vaccines based on outer-membrane proteins have been shown to be efficacious [9] [10] [11] [12] [13] [14] [15] , but the bactericidal antibody responses are strain specific, which limits the utility of these vaccines, except during an epidemic. Certain genetically conserved antigens, such as neisserial surface protein A, also are under investigation as vaccine candidates, but their efficacy may be limited by variable expression of the protein on the outer membrane [16] . Our aim is to develop an NmB conjugate vaccine based on defined innercore lipopolysaccharide (LPS) glycoforms that will induce production of high-affinity IgG antibodies capable of protecting against invasive serogroup B disease.
Previous studies of meningococcal LPS vaccine candidates were not successful because of the complexity of the genetics of LPS biosynthetic genes, the heterogeneity of the LPS outercore structures, the poor immunogenicity of LPS alone (T cellindependent response), and the toxicity of the lipid A moiety [17] . However, lipid A now can be chemically detoxified by altering O-acyl groups (O-deacylated), and conserved LPS epitopes have been identified that can be considered for inclusion in vaccines.
Meningococcal LPS consists of a single oligosaccharide unit (chain) attached to a proximal heptose (Hep; HepI) of innercore diheptose backbone (HepI and HepII) linked to two 2-keto-2-deoxyoctulosonic acid residues and anchored in the membrane by lipid A. Twelve distinct immunotypes of meningococcal LPS (L1-L12) can be defined by monoclonal antibody (MAb) reactivity [18] . The expression of LPS is complex and is controlled by a number of highly regulated genes, some of which are phase variable [19] . The phase variation of outercore LPS that results in heterogeneity of LPS structures occurs by slippage-like mechanisms of homopolymeric DNA tracts (e.g., lgtG) [20] . Inner-core LPS biosynthetic genes lack these homopolymeric tracts, which makes their structure relatively stable (e.g., lsi, icsB, icsA, and galE). However, within the innercore LPS, at least 3 glycoforms have been identified that have phosphoethanolamine (PEtn) at the 3 position or the 6 position or in which PEtn is absent from HepII [21] .
The MAb B5 (IgG3) was one of a series of MAbs raised to a galE (inner-core) LPS mutant of NmB strain H44/76. This MAb was selected because of its broad cross-reactivity with wild-type and LPS mutant strains [21] . The epitope recognized by MAb B5 is expressed in 76% of NmB strains and 70% of N. meningitidis strains, representing all major serogroups (A, C, W135, X, Y, and Z), and is accessible in some fully encapsulated N. meningitidis strains grown in vivo [21] . MAb B5 has opsonophagocytic activity against wild-type strain MC58 and inner-core (galE) LPS mutant strains and has bactericidal activity against a galE mutant, but not the wild-type strain [22] . The aim of the present study was to investigate further the reactivity of MAb B5 with a genetically diverse selection of NmB strains and to correlate binding activity with in vitro and in vivo functional activity.
MATERIALS AND METHODS

Preparation of MAbs.
Murine MAb B5 (IgG3) was raised against the H44/76 galE mutant, as described elsewhere [21] . MAb B5 culture supernatant was prepared using a Sephadex G-25 column (to remove phenol red from the medium) and purified by anion-exchange column chromatography (Resource 15Q anion), using triethanolamine (pH 8.85) as binding buffer and 20 mM triethanolamine containing 1 M sodium chloride (pH 8.85) as elution buffer. The concentration of pure antibody was quantified by measuring absorbance at 280 nm and by a standard protein assay (2 mg/mL protein; Harlan Sera-Lab). The purity of the antibody was confirmed by SDS-PAGE, and the antigenic specificity was determined by LPS ELISA [23] . MAb B5 was ultracentrifuged at high speed (346,000 g for 1 h) to remove any immune complexes and requantitated by protein assay (0.7 mg/mL protein). The ultracentrifuged MAb B5 preparation was used in the serum bactericidal assay and animal protection studies. Control MAbs were anti-porin P1.2 (IgG2a), obtained from the National Institute for Biological Standards and Control (Hertfordshire, UK; 95/696); anticapsular polysaccharide serogroup B MAbs SEAM 3 and SEAM 41, obtained from the Children's Hospital Oakland Research Institute (CHORI; Oakland, CA) [4] ; an irrelevant IgG3 isotype control, from the National Research Council (Ottawa, Ontario; 0157:2; raised against Escherichia coli O157) [24] ; and an irrelevant isotype control, V1G10, from CHORI [4] . Anti-NspA MAb (14C7) was raised against NspA protein [25] . Immunotyping MAbs were obtained from the Rijksinstituut voor Volksgezondheid en Milieu (Bilthoven, The Netherlands).
Bacterial strains and culture conditions. The 28 NmB wild-type strains chosen for this study (e-table 1) were selected from a larger set on the basis of MAb B5 reactivity and their genetic diversity, as determined by multilocus sequence typing [21, 31] . Reactivity of the larger set of strains to selected MAbs was determined by whole-cell ELISA (see the online Appendix). The NmB collection included a number of strains (8047, M986, 2996, and BZ232) that have been used previously in infant rat models of N. meningitidis infection [25] . The gene required for the addition of PEtn at HepII for MAb B5 reactivity, lpt3, has been described elsewhere [35] . The mutant 8047 lpt3 was constructed by the method described by Mackinnon et al. [35] .
The chromosomal DNA from MC58 lpt3 was used to transform strain 8047. The gene disruption was confirmed by polymerase chain reaction. The LPS from a whole-cell preparation of 8047 lpt3 was visualized on a silver-stained tricine-SDS-PAGE gel, and the absence of MAb B5-reactive bands was confirmed by Western blot analysis.
Bacterial strains were grown overnight (18 h) at 37ЊC either on brain-heart infusion (BHI) medium (Oxoid) or chocolate agar medium in an atmosphere of 5% CO 2 . NmB strains for the serum bactericidal assay and animal protection studies were grown in Mueller-Hinton broth (MHB) supplemented with glucose (0.25% wt/vol). Gentle agitation was used to compare results with different growth media (BHI with NAD and hemin, MHB with glucose, and MHB alone); the results obtained with all 3 were comparable to growth in MHB with glucose (0.25% wt/vol), so this was used in all subsequent experiments.
Binding of MAb B5 to encapsulated N. meningitidis using flow cytometry. The ability of the MAbs to bind to the surfaces of live N. meningitidis was determined using a flow cytometric detection method with an indirect fluorescence assay, as described elsewhere [25] . The results were analyzed by counting ∼30,000 particles and determining the percentage of cells that were positive and the geometric mean fluorescence on gated populations (to exclude background fluorescence observed with PBS control alone). Positive-control MAbs included anti-porin P1.2 (specific for the P1.2 serosubtype of the PorA outer-membrane protein) and anti-capsular polysaccharide B (specific for capsular polysaccharide serogroup B). The negative controls consisted of mouse IgG MAb (VIG10) of irrelevant specificity and an IgG3 isotype control MAb.
Bactericidal assay. The bactericidal activity of MAb B5 against strains 8047, M986, and 2996 was determined using 2 methods with different sources of human complement. The first method has been described in detail by Moe et al. [25] . In brief, N. meningitidis was grown in MHB with glucose (0.25% wt/vol), washed in Gey's buffer containing 1% bovine serum albumin (BSA) to a final OD 650 of 0.6, and diluted to yield 300-400 cfu, depending on the strain [25] . The complement was from a healthy adult whose serum lacked intrinsic bactericidal activity and had no detectable anti-capsular polysaccharide B antibodies. After incubation of 12 mL of the bacterial solution in a final volume of 60 mL (20% vol/vol complement and serial dilutions of MAb B5 in Gey's buffer-BSA) for 1 h at 37ЊC on a rotating platform, 20 mL of reaction mixture was transferred to an MHB plate [16] . The bactericidal titers were defined as antibody concentrations resulting in a 50% decrease in colony-forming units per milliliter after 60 min of incubation of bacteria in the reaction mixture, compared with the number of colony-forming units per milliliter at time zero. The second method, in which adult pooled serum from healthy adults as the complement source and an N. meningitidis inoculum of 1000 cfu was used, is described in the online Appendix (e-figure 1) [22, 35] .
Tricine-SDS-PAGE and Western blotting. Whole-cell lysates were prepared for use in tricine-SDS-PAGE and Western blot analysis as described elsewhere [21] . Lysates were boiled in dissociation buffer and then separated on 16.5% tricine gels (Amersham Pharmacia Biotech; 30 mA for 24 h) [37] . Gels were fixed and silver stained, according to the manufacturer's instructions, to visualize LPS bands. LPS was also investigated by Western blot analysis [38] after transfer from the gel to a nitrocellulose membrane (Schleicher and Schuell). Membranes were blocked and then incubated with MAb B5 (diluted 1:5000 with ascites fluid). Primary antibody was detected using an anti-mouse IgG antibody conjugated to alkaline phosphatase (Dako) and developed with a chromogenic substrate.
Measurement of passive protection using an infant rat model. The ability of MAb B5 to confer passive protection against strains 8047, M986, and 2996 was tested in an infant rat model (described by Moe et al. [16] ). In brief, 5-8-day-old pups from litters of outbred Wistar rats (Charles River Laboratories) were randomly redistributed to nursing mothers. Each N. meningitidis strain had been serially passaged 3 times in infant rats. After the third passage, cultures of blood samples from the rats were grown overnight on chocolate agar plates, suspended in sterile skim milk, and stored at Ϫ80ЊC. On the day before challenge, freshly thawed N. meningitidis were inoculated onto chocolate agar and grown overnight at 37ЊC in 5% CO 2 . The next day, 5-20 single colonies were picked and inoculated into broth culture to give a starting OD 650 of 0.1 and then were grown to an OD of ∼0.6 and prepared as described for the bactericidal assay. The MAbs were tested using 2 methods: In the first method, to enhance the sensitivity of the assay, 50 mL of a solution containing different concentrations of MAbs was mixed with the N. meningitidis suspension (50 mL) and administered simultaneously in 100 mL total volume by the intraperitoneal route. In the second method, the animals were pretreated with 100 mL of different concentrations of test or control MAbs administered intraperitoneally 2 h before intraperitoneal challenge with 100 mL of the appropriate dose of N. meningitidis (∼10 3 -10 4 cfu, depending on the strain). Animals were euthanized 18 h after challenge, and heparinized blood samples were obtained by cardiac puncture. Aliquots were plated onto chocolate or BHI agar. The number of colonyforming units per milliliter of blood was determined after overnight incubation of plates at 37ЊC in 5% CO 2 . In earlier experiments, 5-10 mL of blood was obtained from the tail vein of each infant rat at 6 h after challenge. Geometric mean bacteremia (GMB; /mL) was measured, and the number 3 cfu ϫ 10 of positive blood cultures was counted.
Molecular modeling. Molecular modeling of LPS epitopes was carried out as described elsewhere [21] . The starting ge-ometry for all sugars was submitted to a complete refinement of bond lengths, valence, and torsion angles, using the molecular mechanics program MM3(92) (Quantum Chemistry Program Exchanger, Indiana University, Bloomington) [21] . All calculations were performed using the minimized coordinates for the methyl glycoside. The phosphorus groups were generated from standard coordinates and minimum energy conformations found in crystal structures. Calculations were performed using the Metropolis Monte Carlo method. All pendant groups were treated as invariant, except for the phosphorus groups, which were allowed to rotate around Cx-Ox and Ox-P bonds. The starting angles for the oligosaccharide were taken from the minimum energy conformers calculated for each disaccharide unit present in the molecule. Twenty-four-dimensional Metropolis Monte Carlo calculations of the hexasaccharides, with or without PEtn groups attached, were carried out with 5000 macromoves. The graphics were generated using SCHAKAL (E. Keller, Kristal-Logaphisches, Institute der Universität, Freiburg, Germany) [21] .
Statistical analyses. The GMB and range of counts (cfu/ mL) were calculated for each group of animals in each experiment. The results for the groups treated with either MAb B5 or positive-control MAb (anti-porin P1.2 or anti-capsular polysaccharide B MAbs) were compared with the combined results for the negative-control groups (PBS-BSA and irrelevant MAbs) within the same experiment, using a 1-or 2-tailed Student's t test (Microsoft Excel and GraphPad Prism software). Results were only compared within groups of animals treated by the same protocol: pretreatment administration of MAbs or administration of MAbs in combination with N. meningitidis.
RESULTS
Survey of 28 NmB strains.
We selected a set of 28 wellcharacterized, genetically diverse NmB strains on the basis of multilocus sequence typing result or MAb B5 reactivity. These strains are indicated on a dendrogram showing the genetic relationships of a larger set of 107 N. meningitidis strains representing all serogroups in figure 1 [31] . The strains M986, 2996, MC58, and 8047 are indicated in the relevant major lineages (electrophoresis type [ET]-37, A4 cluster, ET-5, and A4 cluster respectively; figure 1). Further details about this set of 28 NmB strains and MAb B5 reactivity determined by various binding assays, including immunodot blot, whole-cell ELISA, surface labeling, and Western blotting, are described in the online Appendix; e-tables 1, 2, and 3; and e-figures 2 and 3. In brief, the survey of the 28 NmB strains by Western blot analysis with MAb B5 demonstrated that there were 3 groups of MAb reactivity (described below). There was a correlation between the pattern of reactivity (type 1, 2, or 3) and the results of surface-labeling experiments. The strains that were type 2 figure 2A, lane 1) . The classification of the 3 representative strains used in the present study (8047, M986, and 2996) is based on reactions with MAb B5 on Western blotting, rather than the total distribution of LPS observed on silver-stained gels.
The total distribution of LPS glycoforms among the 3 types of NmB strains on silver-stained gels is shown in figure 2B . The wild-type strain MC58 was typical of type 1 on LPS gels ( figure 2B, lane 2) , with 2 major bands of sialylated and nonsialylated LPS. The MC58 galE mutant had only the truncated form, as expected (with a faint upper band detected; figure 2B , lane 3). Strain 8047 ( figure 2B, lane 4) was typical of type 2, with sialylated and nonsialylated LPS bands and the truncated form in lesser amounts. Most of the strains classified as type 2 (immunotype L3,7 or L3,7,9), including 8047, have a preponderance of fully extended a-chain glycoforms, as shown by silver-stained gels. The MAb B5-reactive glycoform, which predominates on Western blots, often makes up a very low proportion of the total LPS, and thus the glycoform may not be detected on silver-stained gels. Strain BZ232 was nonreactive with MAb B5 (negative control) on Western blot ( figure 2A, lane 6 ) and has been shown by structural analysis not to have the PEtn at the 3 position of HepII that is essential for reactivity (A. Cox, personal communication). Strain BZ232 can be seen to have a predominant sialylated form, a weaker nonsialylated LPS band, and no truncated form on silver-stained gel ( figure 2B, lane 6) . Our previous studies have identified the gene required to add PEtn to the 3 position of HepII; this gene has been designated "lpt3" [35] . lpt3 mutants and double lpt3 galE mutant strains in MC58 lack PEtn at the 3 position and therefore lack MAb B5 reactivity on Western blot analysis ( figure 2C) .
Complement-mediated bactericidal activity of MAb B5. In the presence of human complement, MAb B5 elicited dosedependent bactericidal activity against 2 of the 3 strains (8047 and 2996 but not M986) ( figure 3A) . The concentrations of MAb B5 necessary to achieve 50% killing of N. meningitidis 8047, 2996, and M986 were 1.35, 4.3, and 148 mg/mL, respectively. The 50% bactericidal concentrations of the anti-capsular polysaccharide control MAb for N. meningitidis 8047, 2996, and M986 were 66, 67, and 69 mg/mL, respectively.
Similar trends in serum bactericidal activity were observed with MAb B5 against N. meningitidis 8047, using a method that tested dilutions of pooled adult serum as the human complement source (e- figure 1) .
Binding of MAb B5 to the bacterial surface. The bactericidal activity of MAb B5 correlated with the observed binding of the MAb to live bacteria, as measured by flow cytometry with 25 mg/mL MAb B5 (figure 3B). High levels of binding were observed with strains 8047 (68.8%) and 2996 (43.8%), which were killed by MAb B5. In contrast, there was poor surface binding with strain M986 (15.1%), which was highly resistant to bactericidal activity. An irrelevant MAb at 25 mg/ mL resulted in 0.55%, 0.58%, and 0.74% surface binding with strains 8047, M986, and 2996, respectively; in contrast, the anti-porin P1.2 MAb at 5 mg/mL resulted in a very high level of binding (99.6%, 98.2%, and 99.2%, respectively).
Passive protection experiments using an infant rat model. The ability of MAb B5 to confer passive protection against meningococcal bacteremia was assessed in 5-8-day-old infant rats challenged by the intraperitoneal route with 3 NmB strains (8047, M986, and 2996), using 2 models of protection (as described in Materials and Methods). MAb B5 provided protection against strain 8047, partial protection against strain 2996, and no protection against strain M986, which correlated with the activity of these strains in the bactericidal and binding assays. 5) . "Type 2" refers to strains with predominantly the truncated glycoform (lanes 3 and 4) . Type 3 refers to strains with the mixture of both extended sialylated and nonsialylated glycoforms and truncated glycoform (lane 1). B, Silver-stained tricine gel of whole-cell preparations of N. meningitidis serogroup B strains, corresponding to the Western blot described in A. C, Western blot of whole-cell lysates of N. meningitidis L3 wild type (lane 1), L3 galE lipopolysaccharide (LPS) mutant (lane 2), and L3 double lpt3 galE mutant (lane 3), separated by SDS-PAGE, transferred to nitrocellulose filter, blocked and incubated with MAb B5, and detected as described in A. This blot demonstrated that MAb B5 preferentially binds to truncated (galE) LPS glycoforms rather than to extended sialylated L3 LPS. MAb B5 does not bind to LPS of the lpt3 mutant, which indicates that phosphoethanolamine is required at 3 position of HepII for MAb B5 reactivity.
The results of passive protection with the first model, in which MAb B5 and the NmB strains (8047, 2996, and M986) were administered simultaneously, are shown in table 1. This demonstrated that a dose of MAb B5 as low as 2 mg was able to protect against strain 8047. In contrast, a dose of 10 mg of MAb B5 was able to partially protect against strain 2996, resulting in a GMB that was !3% of that of animals challenged with strain 2996 together with a negative-control irrelevant MAb ( vs. cfu/mL; , by 1-tailed Stu- 3 3 2.3 ϫ 10 93.0 ϫ 10 P ! .05 dent's t test) (table 1). No protection against strain M986 was achieved with 7.0 mg of MAb B5. The results of the second model, in which animals were pretreated with MAb B5 before challenge with the NmB strains, are shown in table 2. This model demonstrated similar protection against strain 8047; a dose of 50 mg of MAb B5 produced complete protection against this strain. However, no protection was observed with a dose of 25 mg of MAb B5 against strain 2996 or with a dose of up to 100 mg against strain M986 (table 2). As expected, 50 mg of MAb B5, administered at the same time as the nonreactive group B strain BZ232, did not confer protection (data not shown).
DISCUSSION
In this study, we have demonstrated that NmB strains display 3 patterns of LPS glycoforms (types 1, 2, and 3), which are distinguished by having different ratios of the extended sialylated, nonsialylated, and truncated MAb B5-reactive glycoforms, as determined by Western blot (figure 2). The assignment of the 3 strains to these 3 groups is based solely on the Western blot pattern with MAb B5 and not on the total distribution of LPS glycoforms detected on silver-stained gels. Serial passaging of N. meningitidis strains 3 times in infant rats does not change the glycoform patterns from those seen before passage (data not shown). Flow cytometric analysis shows that MAb B5 preferentially binds to the surface of type 2 strains, such as 8047, in which the truncated LPS MAb B5-reactive glycoform is highly prevalent on Western blots (figure 3B). MAb B5 binds less well to the surface of type 3 strains, such as 2996, in which there is a mixture of fully extended and truncated LPS on Western blots. The lowest level of MAb B5 binding is observed with type 1 strains, such as M986, in which the LPS detected on Western blots is fully extended. The different degrees of MAb B5 binding correlate with the results of in vitro and in vivo functional studies. Thus, MAb B5 elicits complement-mediated bactericidal activity against 8047 (type 2) but is less active against 2996 (type 3) and shows no bactericidal activity against strain M986 (type 1) ( figure 3A ). These data NOTE. BSA, bovine serum albumin; GMB, geometric mean bacteremia. a Challenge doses were cfu for strain 8047, cfu for strain 3 3 4.8 ϫ 10 4.6 ϫ 10 M986, and cfu for strain 2996. 3 5.7 ϫ 10 b For calculation of the geometric mean level of NmB in culture, a value of 10 cfu/mL was assigned to sterile cultures. The GMB in cultures from animals that received MAb B5 was compared with that in the combined group of negative-control animals that received irrelevant MAbs or PBS-BSA, using a 2-tailed Student's t test. Ranges are to .
correlated well with the passive protection (decrease in bacteremia) seen with MAb B5 in the infant rat model (table 1) . MAb B5 was highly protective against bacteremia caused by strain 8047 (type 2), partially protective against strain 2996 (type 3), and not protective against strain M986 (type 1). In contrast, MAb B5 demonstrated comparable high levels of opsonic activity against strains 8047 and M986 and lower levels of opsonic activity against 2996 in an opsonophagocytosis assay with ethanol-fixed fluorescently labeled bacteria, human donor polymorphonuclear leukocytes, and human complement (efigure 4) [22] .
The ability of MAb B5 to bind to the surface and confer protection against strains with the truncated glycoform is not surprising. MAb B5 was raised against whole cells of a truncated L3 (H44/76) galE mutant in which the portion of inner core (MAb B5 epitope) is less accessible than on the extended LPS glycoform. To understand how MAb B5 binds to the innercore truncated portion, we compared the 3-dimensional molecular model of the fully extended wild type to that of the truncated mutant (figure 4; see http://ibs-isb.nrc-cnrc.gc.ca/ibs/ facilities/molecularmodelling_e.html). Although computer-generated 3-dimensional models have limitations, they can be helpful in understanding the epitopes that potentially could occur in vivo. In these models, the MAb B5 epitope is less accessible in the wild-type extended glycoform and more exposed in the truncated glycoform. The MAb B5 epitope requires PEtn at the 3 position of HepII and N-acetyl glucosamine (GlcNAc) and has a partial dependence on glucose. These structures are highlighted in the inner-core model ( figure 4) . Therefore, the accessibility of this epitope to MAb B5 may be restricted in the full-length wild-type structure (figure 4). The 3-dimensional space-filling minimum-energy molecular model (created by Metropolis Monte Carlo calculation) of the inner-core LPS epitope demonstrates the importance of PEtn at the 3 position of HepII in the L3 galE mutant and a fully extended L3 wildtype for MAb B5 binding. The model also demonstrates how the PEtn could be the immunodominant residue (figure 4). The model of the lpt3 mutant with the PEtn removed (MAb B5 nonreactive) demonstrates an altered epitope in which glucose and GlcNAc may be more critical for MAb binding ( figure 4) .
In our survey of 28 genetically diverse group B strains that were reactive to MAb B5, a majority of strains displayed the type 2 truncated glycoform pattern (58%). The type 1 and type 3 patterns were observed in 21% and 21% of NmB strains, respectively. In surface-labeling experiments in which live bacterial cells were used, MAb B5 bound minimally to the surface of representative strains of the type 1 and type 3 patterns on Western blot (figure 3B). However, these type 1 and type 3 N. meningitidis strains reacted with the same strength as type 2 strains in surface-labeling experiments in which ethanol-fixed bacteria with MAb B5 were used (e-tables 2 and 3). Thus, the epitope defined by the MAb B5 is present on type 1 and type 2 strains when they are ethanol fixed but is not readily accessible on the surface of live bacteria. In contrast, the epitope is accessible on the surface of the live type 2 strains. NOTE. BSA, bovine serum albumin; GMB, geometric mean bacteremia. a Challenge doses were cfu for strain 8047, cfu for strain 3 3 5.0 ϫ 10 4.6 ϫ 10 M986, and cfu for strain 2996. 3 5.7 ϫ 10 b For calculation of the geometric mean level of NmB in culture, a value of 10 cfu/mL was assigned to sterile cultures. The GMB in cultures from animals that received MAb B5 was compared with that in the combined group of negative-control animals that received irrelevant MAbs or PBS-BSA, using a 2-tailed Student's t test. Ranges are to
Two regimens were compared in the passive protection model, in which 5-8-day-old outbred Wistar infant rats were used: (1) simultaneous administration of MAb B5 antibody and N. meningitidis and (2) pretreatment with MAb B5 antibody 2 h before N. meningitidis challenge. Both models demonstrated similar protection against the 3 N. meningitidis strains (tested in laboratories at the John Radcliffe Hospital, Oxford, and CHORI). The results of the model in which MAb B5 was administered simultaneously with bacterial challenge followed the same trends in protection that the pretreatment model did, except that higher doses of MAb were required for protection in the pretreatment model (compare tables 1 and 2). For example, MAb B5 was completely protective at a dose of 2 mg when it was administered with strain 8047, but 40 mg was required to achieve the same effect in the pretreatment model. For strain 2996, partial protection was observed at a dose of 10 mg administered at the same time as the bacterial challenge, but no protection with this strain was observed in animals pretreated with 25 mg. For strain M986, no protection was observed with either pretreatment (17.5 mg) or the more sensitive model (7 mg). Therefore, the choice of infant rat model can determine the most reactive (pretreatment model) or the least reactive (simultaneous injection model) MAbs, depending on the results required. In both models, the anti-porin P1.2 MAb was completely protective against all 3 N. meningitidis strains at doses of 5-20 mg in the pretreatment model (table 2) and 0.8-4 mg/mL in the more sensitive model (table 1) . The anti-capsular polysaccharide B MAb was more variable in its ability to protect; doses from 10 to 26 mg were required for protection in the pretreatment model (table 2) and from 4 to 10 mg in the more sensitive model (table 1) .
In addition to the problem of accessibility of inner-core structures by MAb B5 to the extended wild-type L3 LPS structure (figure 4), there are a number of reasons that may explain the preference for MAb B5 binding to truncated forms. These include the higher avidity of MAb B5 to truncated LPS glycoforms, compared with that of the fully extended wild-type LPS, and the effect of differences in complement binding. These possibilities are currently under investigation.
In summary, MAb B5 confers passive protection in infant rats against strain 8047, confers partial protection against strain 2996, and does not confer protection against strain M986. These results suggest that MAb B5 is only able to protect against strains in which truncated LPS is the major LPS glycoform detected on Western blot with MAb B5, even though the truncated glycoform may be expressed in such low amounts that it is not detected on silver-stained gels. The lack of MAb B5 binding to strains with sialylated and nonsialylated extended LPS on Western blot correlates with low binding in surfacelabeling experiments and poor functional activity in vitro (serum bactericidal activity) and in vivo (infant rat model). NmB strains (such as 2996) that express truncated and nonsialylated glycoforms in equal amounts (as detected by Western blot) demonstrate some MAb B5 binding on surface labeling. Therefore, there is some functional activity in vitro (bactericidal and opsonophagocytic activity; see the online Appendix) and partial protection in vivo against this strain (reduction in bacteremia; seen using the model in which MAb B5 and N. meningitidis are administered simultaneously). Although MAb B5 has been shown, by whole-cell ELISA and Western blot, to bind to 76% of NmB strains [21] , the ability of the MAb to bind to the surface of live bacteria or to completely protect against these strains depends on the presence of the MAb B5-reactive truncated glycoform. On Western blot, 58% of 28 NmB strains surveyed were shown to be type 2; 21% were type 3, and 21% were type 1. Therefore, the effectiveness of a vaccine based only on this truncated glycoform may be limited. Future conjugate vaccines need to elicit specific inner-core LPS antibodies that recognize this MAb B5 epitope in both the complete extended wild-type sialylated and nonsialylated LPS glycoforms, in addition to truncated glycoforms. These studies are currently under way.
